Search This Blog

Tuesday, June 4, 2019

FDA accepts Eli Lilly’s NDA for type 2 diabetes triple combination tablet

The FDA has accepted Boehringer Ingelheim and Eli Lilly’s (NYSE:LLY) New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes.
Empagliflozin is marketed as Jardiance in U.S.
Linagliptin is marketed as Tradjenta tablets in U.S.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)